ProfileGDS5678 / 1420255_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 61% 61% 60% 60% 64% 66% 61% 60% 61% 61% 60% 62% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8127363
GSM967853U87-EV human glioblastoma xenograft - Control 23.6436361
GSM967854U87-EV human glioblastoma xenograft - Control 33.6750461
GSM967855U87-EV human glioblastoma xenograft - Control 43.5314460
GSM967856U87-EV human glioblastoma xenograft - Control 53.5740760
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8714164
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0271966
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6554361
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5977360
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6128161
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6620161
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5703460
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7445162
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6627461